QUOTE AND NEWS
Reuters  Jul 15  Comment 
Danish investment company Novo A/S said it bought hearing technology firm Sonion from Swedish private equity firm Altor, entering a market in which Denmark has been a...
Motley Fool  Jul 8  Comment 
Dividends and growth -- watch below to learn more about these stocks
Benzinga  Jun 27  Comment 
Below are the top drug manufacturers-other stocks on the NYSE and the NASDAQ in terms of dividend yield. Teva Pharmaceutical Industries (NYSE: TEVA) has a dividend yield of 2.20%. Teva Pharmaceutical's shares closed at $52.45 on Thursday. Novo...
SeekingAlpha  Jun 26  Comment 
By PLM Investments: Novo Nordisk (NVO) is generally recognized as one of the world's leaders in diabetes drug development and sales, with over $2B in R&D spending in 2013, and a 27% market share in diabetes care - higher than any other company. It...
Benzinga  Jun 25  Comment 
OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company, yesterday hosted a webcast presenting outstanding interim six-month results from a Phase 2 study of its long-acting human growth hormone product Lagova to...
FiercePharma  Jun 25  Comment 
This has not been a great year for Denmark's Novo Nordisk ($NVO) so far--the diabetes drugmaker failed to post double-digit sales growth in first quarter for the first time in four years. But the company believes its 2014 performance is just a...
Motley Fool  Jun 20  Comment 
Novo's position in diabetes looks safe, while Lilly has bold plans to be a share-gainer.
SeekingAlpha  Jun 20  Comment 
By Spencer Osborne: When we look at the developing anti-obesity space, we often think of Vivus (VVUS), Arena Pharmaceuticals (ARNA), and Orexigen (OREX). These three companies have been the center of attention, because two already have products...
Motley Fool  Jun 18  Comment 
Patent expirations and competitors' news drugs may pose risks to Novo Nordisk's dividend.
Wall Street Journal  Jun 16  Comment 
Novo Nordisk has been on the lookout for potential takeover targets but sees little strategic reason to jump into the deal-making wave sweeping the global pharmaceuticals sector.





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki